X

Trial Profile

A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 091 (Primary) ; Capecitabine; Cisplatin
Indications Gastric cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms FACING

Most Recent Events

24 Nov 2015 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials Record.
05 Mar 2015 Status changed from recruiting to completed, as reported by United Kingdom Clinical Research Network record.
18 Jul 2014 Accrual to date is 20% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com